Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05419518 · ClinicalTrials.gov registry record · Phase 2
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas
A Phase 2 study of Metastases, Neoplasm and Neoplasm Metastases, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 7
- Study locations
NCT05419518 is a Phase 2 study of Metastases, Neoplasm and Neoplasm Metastases that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 124 participants. The trial reports 7 study locations across 1 state.
The verdict
NCT05419518, a Phase 2 study of Metastases, Neoplasm and Neoplasm Metastases, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 7
- Study locations
Study Summary
The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases
Conditions Studied
Interventions
- BIOLOGICAL EXTERNAL BEAM RADIATION
Study Locations (7)
New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital - Hamilton
- RWJBarnabas Health - Monmouth Medical Center Southern Campus - Lakewood
- RWJBarnabas Health - Saint Barnabas Medical Center - Livingston
- Robert Wood Johnson University Hospital - New Brunswick
- Cancer Institute of New Jersey - New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital - Somerset
- RWJBarnabas Health - Community Medical Center - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2023-03-16 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05419518
The ClinicalTrials.gov registry entry for NCT05419518 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastases, Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which EXTERNAL BEAM RADIATION is the first listed.
NCT05419518 reports 7 study locations spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05419518 about?
NCT05419518 is a clinical study titled "Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas". The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated bio...
What is the current status of trial NCT05419518?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2023-03-16. Estimated completion is 2027-04-01.
What conditions does trial NCT05419518 study?
This clinical trial studies the following conditions: Metastases, Neoplasm, Neoplasm Metastases.
What interventions are being tested in trial NCT05419518?
The interventions under investigation include: EXTERNAL BEAM RADIATION (BIOLOGICAL).
Who is sponsoring clinical trial NCT05419518?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05419518 being conducted?
This trial has 7 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastases, Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
COMPLETED · Phase 2
-
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
COMPLETED · Phase 3
-
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.